Biohealthinvestor - biohealthinvestor.com - BioHealth Investor
General Information:
Latest News:
Shouldn’t VIVUS Raise Capital Now? (VVUS) 24 Feb 2012 | 07:49 am
While we have started mostly using The Wire at 247wallst.com for our biotech and active trader posts (among many other aspects 50 to 100 times per day), we have a question for BioHealthInvestor reader...
Can Human Genome Really Double Its Stock Price? (HGSI) 29 Dec 2011 | 04:30 am
At the end of December, we usually review the biotech sector to see which stocks have the most upside for the year ahead. The basis of the “implied upside” is the consensus mean estimate from Thomson...
Alimera Implosion Analysis, What Is Next (ALIM, PSDV) 12 Nov 2011 | 11:17 am
Alimera Sciences, Inc. (NASDAQ: ALIM) is the latest of the drug implosions and this one looks even worse than just severely damaging. The FDA’s complete response letter is really a request for additi...
Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN) 9 Nov 2011 | 08:58 am
Tuesday has been an awful day for shareholders of Targacept Inc. (NASDAQ: TRGT). The company shares lost more than half of their value on news that initial test results from the Phase III antidepress...
Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY) 5 Nov 2011 | 03:25 am
Vical Inc. (NASDAQ: VICL) and VIVUS, Inc. (NASDAQ: VVUS) are both running higher this Friday on news that Credit Suisse initiated both biotech outfits with “Outperform” ratings. What matters more tha...
Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX... 20 Oct 2011 | 12:34 am
Earnings season is afoot and we wanted to see how the analysts are ranking the top biotech stocks before these companies begin their earnings reports. We pulled the top biotech and biohealth related ...
Odds-Making on a Human Genome Sciences Acquisition (HGSI, GSK, BIIB, MRK) 19 Oct 2011 | 05:19 am
Human Genome Sciences Inc. (NASDAQ: HGSI) is surging on reports that GlaxoSmithKline PLC (NYSE: GSK) could be set to make a $25.00 per share offer to acquire the company. The report surfaced in the D...
Unusual Analyst Upgrade & Endorsement for Cell Therapeutics (CTIC) 14 Oct 2011 | 01:05 am
Cell Therapeutics, Inc. (NASDAQ: CTIC) is a controversial stock in the field of cancer and the company is still aiming for a 2012 debut market launch for its pixantrone drug candidate. In the last co...
Private Equity Changes CRO Landscape With PPD Buyout (PPDI, CRL, CVD, PRXL) 4 Oct 2011 | 01:56 am
The world of contract research organizations is changing. The unexpected news hit the wire this Monday that Pharmaceutical Product Development, Inc. (NASDAQ: PPDI) is being acquired. This was no gob...
More Signs of Life for Obesity Drugs (VVUS, OREX, ARNA) 16 Sep 2011 | 03:25 am
VIVUS Inc. (NASDAQ: VVUS) is getting yet one more sign of life for its Qnexa drug aimed at treating obesity. The emerging drug outfit has reached an agreement with the FDA on resubmitting its new dru...
